trial

Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory Hallucination

NCTId NCT04629352
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 72 (estimated)
Sponsored by National Institute of Mental Health and Neuro Sciences, India
Primary completion 2026-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
72 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-04-02
Primary completion
2026-08-31
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)

Sponsors

National Institute of Mental Health and Neuro Sciences, IndiaLead Sponsor

Investigators

2
Anushree Bose, PhDPrincipal Investigator
Ganesan Venkatasubramanian, MD, PhDStudy Chair

Sites

1 total
Bengaluru, India

Facts & assertions

4 sourced
Enrollment
72
Phase
NA
Primary Completion Date
2026-08-31
Status
RECRUITING
relationships
The graph out of here
drug
Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)
drug
lead_sponsor
National Institute of Mental Health and Neuro Sciences, India
company
indication
Hallucinations
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Anushree Bose, PhD
person
Ganesan Venkatasubramanian, MD, PhD
person